346 related articles for article (PubMed ID: 18285385)
1. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
Boyd KA; Briggs AH
Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
[TBL] [Abstract][Full Text] [Related]
4. The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness.
Højgaard B; Olsen KR; Pisinger C; Tønnesen H; Gyrd-Hansen D
Scand J Public Health; 2011 Dec; 39(8):785-96. PubMed ID: 21976052
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
[TBL] [Abstract][Full Text] [Related]
6. Determining the cost-effectiveness of a computer-based smoking cessation intervention in primary care.
Smith MY; Cromwell J; DePue J; Spring B; Redd W; Unrod M
Manag Care; 2007 Jul; 16(7):48-55. PubMed ID: 17907712
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database.
Olsen KR; Bilde L; Juhl HH; Kjaer NT; Mosbech H; Evald T; Rasmussen M; Hiladakis H
Eur J Health Econ; 2006 Dec; 7(4):255-64. PubMed ID: 16816946
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression.
Barnett PG; Wong W; Hall S
Addiction; 2008 May; 103(5):834-40. PubMed ID: 18412763
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a family physician delivered smoking cessation program.
Buck DJ; Richmond RL; Mendelsohn CP
Prev Med; 2000 Dec; 31(6):641-8. PubMed ID: 11133329
[TBL] [Abstract][Full Text] [Related]
11. The total lifetime health cost savings of smoking cessation to society.
Rasmussen SR; Prescott E; Sørensen TI; Søgaard J
Eur J Public Health; 2005 Dec; 15(6):601-6. PubMed ID: 16014659
[TBL] [Abstract][Full Text] [Related]
12. [Predictors of smoking cessation in group-based behavioral intervention programme--research findings in 2001-2007].
Broszkiewicz M; Sobala W; Drygas W
Przegl Lek; 2008; 65(10):634-40. PubMed ID: 19189567
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease.
Quist-Paulsen P; Lydersen S; Bakke PS; Gallefoss F
Eur J Cardiovasc Prev Rehabil; 2006 Apr; 13(2):274-80. PubMed ID: 16575284
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
15. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
16. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
17. Establishment and evaluation of a smoking cessation clinic in Hong Kong: a model for the future service provider.
Abdullah AS; Hedley AJ; Chan SS; Ho WW; Lam TH;
J Public Health (Oxf); 2004 Sep; 26(3):239-44. PubMed ID: 15454590
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients.
Christenhusz LC; Prenger R; Pieterse ME; Seydel ER; van der Palen J
Nicotine Tob Res; 2012 Jun; 14(6):657-63. PubMed ID: 22180589
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of smoking-related disease in Thailand: a prevalence-based analysis.
Leartsakulpanitch J; Nganthavee W; Salole E
J Med Assoc Thai; 2007 Sep; 90(9):1925-9. PubMed ID: 17957939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
